Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence‐free survival

2021 ◽  
Author(s):  
Sarayu Subramanian ◽  
Gang Han ◽  
Natalie Olson ◽  
Stanley P. Leong ◽  
Mohammed Kashani‐Sabet ◽  
...  
Keyword(s):  
Recurrence Rate ◽  
Regional Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival

Impact of extended lymphadenectomy on morbidity and regional recurrence-free survival in melanoma patients

2017 ◽  
Vol 29 (5) ◽  
pp. 515-521
Author(s):  
Johannes Baur ◽  
Katrin Mathe ◽  
Anja Gesierich ◽  
Gerhard Weyandt ◽  
Armin Wiegering ◽  
...  
Keyword(s):  
Regional Recurrence ◽  
Recurrence Free Survival ◽  
Extended Lymphadenectomy ◽  
Free Survival ◽  
Melanoma Patients

scholarly journals Maintenance phototherapy for the treatment of early stage mycosis fungoides

2019 ◽  
Author(s):  
Soumaya Gara ◽  
Noureddine Litaiem ◽  
Takwa Bacha ◽  
Djamila Sandra OUEDRAOGO ◽  
Yosra Jmour ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Recurrence Rate ◽  
Early Stage ◽  
Maintenance Phase ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Early Stages ◽  
Stage Disease ◽  
Narrowband Uvb

Abstract Background : Phototherapy has been a mainstay of treatment of early stages (Ia-IIa) of mycosis fungoides (MF). Despite this, there is no internationally standardized phototherapy regimen schedule for MF. Efficacy of maintenance therapy is poorly evaluated especially in patients with dark phototype (IV-VI). Methods : Thirty patients with early stage MF treated with PUVA therapy and narrowband UVB therapy from January 2004 to January 2016 at a single institution were retrospectively reviewed. Recurrence rate and recurrence-free survival were assessed in patients who received maintenance phase and in those who underwent follow-up. Results : Seventeen patients had patch stage disease while 16 patients had plaque stage disease. Most of the patients (22, 73%) had dark phototype. Nineteen patients received NB-UVB therapy, while 11 patients received PUVA. Mean follow-up period was 36,1 + 13 months. There was no significant association between the recurrence rate and recurrence free survival in patients who received maintenance phase and those who underwent follow-up. Conclusions: Phototherapy is a safe and effective treatment option for patients with early stage MF. Evidence supporting the use of maintenance phase for the treatment of early stages MF is lacking.

scholarly journals Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma

2018 ◽  
Vol 79 (05) ◽  
pp. 495-500 ◽  
Author(s):  
John Marinelli ◽  
Jamie Van Gompel ◽  
Michael Link ◽  
Eric Moore ◽  
Kathryn Van Abel ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rates ◽  
Regional Recurrence ◽  
Recurrence Free Survival ◽  
Cervical Lymph Nodes ◽  
Term Survival ◽  
Free Survival ◽  
Tertiary Referral Center ◽  
Neck Disease ◽  
Neck Metastases

Objectives Neck metastases in patients with esthesioneuroblastoma (ENB) constitute the most significant predictor of poor long-term survival. Recently, researchers discovered the existence of dural lymphatic channels that drain to the cervical lymph nodes. From this physiologic basis, we hypothesized that patients with ENB who develop dural invasion (DI) would exhibit a proclivity for neck metastases. Design Retrospective review. Setting Tertiary referral center. Participants All patients treated for ENB from January 1, 1994 to December 31, 2015. Main Outcome Measures Incidence, laterality, and recurrence rate of neck metastases by DI status. Results Sixty-one patients were identified (38% female; median age 49, range, 10–80), 34 (56%) of whom had DI and 27 (44%) did not. Of patients with DI, 50% presented with or developed neck disease following treatment compared with just 22% of those without DI (p = 0.026). Bilateral neck disease was more common in patients with DI (11/34, 32%) compared with those without (2/27, 7%) (p = 0.018). Five-year regional recurrence-free survival rates were 88% for those without and 64% for those with DI (p = 0.022). Kadish C patients with DI were more likely to develop regional recurrence when compared with Kadish C without DI and Kadish A/B (p = 0.083). Further, Kadish C patients with DI displayed worse overall survival than Kadish C without DI and Kadish A/B. Kadish D patients displayed the worst overall survival. The difference in overall survival among these four groups was significant (p < 0.001). Conclusion DI by ENB is associated with increased incidence of cervical nodal metastases, bilateral neck disease, worse regional recurrence-free survival, and poorer overall survival. These data support the division of Kadish C by DI status.

scholarly journals Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study

2019 ◽  
Vol 47 (6) ◽  
pp. 2492-2498 ◽  
Author(s):  
Tianjiao Lyu ◽  
Lu Guo ◽  
Xiaojun Chen ◽  
Nan Jia ◽  
Chao Gu ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Endometrial Carcinoma ◽  
Recurrence Rate ◽  
Cox Regression ◽  
Premenopausal Women ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Ovarian Preservation ◽  
Significant Difference ◽  
Stage Ia

Objective This study aimed to retrospectively investigate the safety of ovarian preservation of premenopausal women with stage 1a endometrial carcinoma. Methods We performed a population-based study to identify surgically treated stage Ia endometrial cancer of premenopausal women who were diagnosed between August 1989 and December 2015 in our center. Survival outcomes and recurrence rate were examined for premenopausal women who underwent ovarian preservation. Recurrence-free survival rates were calculated following generation of Kaplan–Meier curves and were compared with the log-rank test. Cox regression analysis was performed to identify the independent factors affecting the recurrence rate. Results Patients with ovarian preservation tended to be significantly younger at diagnosis, have less myometrial invasion, and were less likely to undergo lymphadenectomy compared with women treated with bilateral salpingo-oophorectomy. There was no significant difference in recurrence-free survival between the two groups. In the Cox regression model, ovarian preservation remained an independent prognostic factor for improved overall survival. Conclusion Ovarian preservation does not have a negative effect on oncological outcomes. Ovarian preservation can be applied to premenopausal women with stage Ia endometrial carcinoma.

scholarly journals Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.

2020 ◽  
Vol 92 (1) ◽  
pp. 17-20
Author(s):  
Marco Capece ◽  
Lorenzo Spirito ◽  
Roberto La Rocca ◽  
Luigi Napolitano ◽  
Roberto Buonopane ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Recurrence Rate ◽  
Blue Light ◽  
White Light ◽  
Transurethral Resection ◽  
Therapeutic Option ◽  
Bladder Tumour ◽  
Photodynamic Diagnosis ◽  
Recurrence Free Survival ◽  
Free Survival

Background: Bladder cancer is the eleventh most commonly diagnosed cancer worldwide. The recurrence rate of this cancer can be very high, up to 45%. Photodynamic diagnosis (PDD) is more sensitive than standard procedures for the detection of malignant tumours. The aim of the study was to evaluate oncological outcomes in white light TURB (WL-TURB) and hexaminolevuninate blue light TURB (Hal-TURB). Patients and methods: This was a retrospective longitudinal single-center study. In the period between January 2016 and October 2016 WL-TURB was the only therapeutic option available. From November 2016 until April 2017 all TURBs were fluorescence-guided (Hal-TURB). Kaplan-Meier curves have been used to estimate recurrence free survival rates. Results: One hundred and eleven patients underwent Hal- TURB and 137 underwent WL-TURB. Recurrence rate after 12 months was 19.8% (22 out of 111 patients) and 37.2% (51 out of 137 patients) in HAL-group and WL-group respectively (p < 0.01). The recurrence-free period was longer in HAL-group rather than WL-group (8.9 months vs 7.3 months, p < 0.05). Moreover, the recurrence rate during the first 6 months was 3.7% in patients who underwent HAL-TURB and 16% in those who received WL-TURB (p < 0.01). Conclusion: The results of the study show that recurrence-free survival was longer in patients undergoing HAL-TURB compared to the patients who received standard WL-TURB.

scholarly journals Adjuvant intravesical chemotherapy with titanium glycerosolvate aquacomplex versus BCG therapy in patients with high risk nonmuscle-invasive bladder cancer

2020 ◽  
Vol 16 (3) ◽  
pp. 126-134
Author(s):  
A. V. Zamyatin ◽  
V. O. Mager ◽  
A. S. Orlov ◽  
K. A. Il'in ◽  
S. E. Zavatskiy ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Group ◽  
High Risk ◽  
Recurrence Rate ◽  
Control Group ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

Objective: to compare recurrence rate, progression rate and recurrence-free survival in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) after adjuvant intravesical chemotherapy (IVCT) with titanium glycerosolvate aquacomplex (TGA) versus intravesical BCG therapy.Material and methods. In a retrospective multicenter clinical study initially were included 126 patients with NMIBC. Of all 126 patients, 94 patients with high-risk NMIBC were selected and divided into 2 groups using a pseudo randomization with propensity score matching to minimize systematic differences in the process of forming groups. The treatment group (n = 55) consisted of patients with high-risk NMIBC who received a 6-week course of adjuvant IVCT with TGA. In the control group (n = 39) patients received an induction 6-week course of adjuvant intravesical BCG therapy, 19 (49 %) of 39 patients received maintenance therapy. Both methods were compared according to recurrence rate, progression rate and recurrence-free survival. Significance of difference was set at p <0.05.Results. The compared groups of patients were well balanced in terms of clinical and morphological characteristics and the main risk factors for recurrence and progression of non-muscle-invasive bladder cancer, no significant differences were found between the groups (p >0.5). The recurrence rate in treatment and control groups was 33 % and 23 %, respectively (p = 0.31). The disease progression was observed in 1 (2 %) patient in the treatment group and in 4 (13 %) patients in the control group (p = 0.08). The median disease-free survival in both groups of patients was not reached at the time of analysis. Three- and five-year recurrence-free survival in the treatment group of patients were 71 % and 62 %, respectively; in the control group — 76 % and 72 %, respectively. There were no significant differences between recurrence-free-survival curves of the treatment and control groups (p = 0.58).Conclusion. Adjuvant IVCT with TGA has demonstrated a clinical effectiveness comparable to intravesical BCG therapy and it can be used as an alternative method of treatment in patients with high-risk NMIBC.

scholarly journals Contralateral Lower Neck Sparing Radiotherapy in Stage N1 Nasopharyngeal Carcinoma: Long-Term Survival Outcomes and Late Toxicities

2021 ◽  
Vol 11 ◽  
Author(s):  
Zhuang Sun ◽  
Jingyun Wang ◽  
Runda Huang ◽  
Xiaohui Wang ◽  
Chunyan Chen ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Regional Recurrence ◽  
Survival Outcomes ◽  
Recurrence Free Survival ◽  
Term Survival ◽  
Free Survival ◽  
Long Term Survival ◽  
Failure Patterns ◽  
Lower Neck

PurposeTo explore the feasibility of contralateral lower neck sparing radiotherapy for patients with stage N1 nasopharyngeal carcinoma (NPC) by analyzing long-term survival outcomes and late toxicities.MethodsData of patients with stage N1 NPC who were treated with contralateral lower neck sparing radiotherapy between January 2013 and December 2015 were analyzed. These patients were all staged by magnetic resonance imaging (MRI), and all received irradiation to the upper neck (levels II, III, and Va) bilaterally along with ipsilateral levels IV and Vb, without irradiation of the contralateral lower neck. Treatment outcomes, regional failure patterns, and late toxicities were examined.ResultsA total of 275 eligible patients with stage N1 NPC were included in the present study. The median follow-up period was 62 months (range, 3–93 months). The 5-year overall survival (OS), distant metastasis-free survival (DMFS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), locoregional recurrence-free survival (LRRFS), and progression-free survival (PFS) rates were 90.5, 91.3, 94.7, 95.3, 91.2, and 81.7%, respectively. A total of 13 patients (4.7%) developed regional recurrence, all of which occurred in the field and not out of the field. Among 254 patients with available data on late toxicities, the most common late toxicity was xerostomia. No late injuries occurred in the carotid arteries, brachial plexus, or spinal cord. In addition to one case (0.4%) of neck fibrosis and three cases (1.2%) of hearing loss, there were no other grade 3–4 late toxicities observed.ConclusionsContralateral lower neck sparing radiotherapy would be safe and feasible for patients with stage N1 NPC, with the potential to improve the long-term quality of life of patients.

scholarly journals Comparison of Recurrence of Non-muscle Invasive Bladder Carcinoma after Transurethral Resection with Hexaminolevulinate Photodynamic Diagnosis or Regular Cystoscopy

2021 ◽  
Author(s):  
Fokke Hoogeveen ◽  
Marco Blanker ◽  
Evelyne Cauberg ◽  
Martijn Steffens
Keyword(s):  
Recurrence Rate ◽  
White Light ◽  
Transurethral Resection ◽  
Bladder Carcinoma ◽  
Photodynamic Diagnosis ◽  
Recurrence Free Survival ◽  
Odds Ratios ◽  
Free Survival ◽  
White Light Cystoscopy ◽  
Muscle Invasive

Abstract Purpose: Comparison of recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis (PDD) or regular white light cystoscopy (WLC).Methods: We included patients with newly suspected non-muscle invasive bladder carcinoma in this retrospective cohort study and compared those undergoing transurethral resection by WLC and PDD. The primary outcome was the difference in the recurrence rate after 60 months’ follow-up, but we also stratified recurrence by risk groups. The mean recurrence-free survival was compared between the cohorts. Odds ratios or hazard ratios are reported with 95% confidence intervals.Results: The WLC and PDD cohorts comprised 124 and 91 subjects, respectively. There were no significant differences in recurrence rates at 6 months (recurrence rate 9/123; 7.3%), 12 months (17/118; 14.4%), or 60 months (39/102; 38.2%), with odds ratios of 1.23 (0.48–3.25; P=0.64), 1.32 (0.67–2.62; P=0.42), and 1.12 (0.70–1.79; P=0.65), respectively. Further analysis showed no significant effect of PDD on recurrence by risk group or on mean recurrence-free survival (hazard ratio, 1.12; 0.70–1.79).Conclusion: Photodynamic diagnosis with hexaminolevulinate did not reduce the recurrence of non-muscle invasive bladder carcinoma compared to standard white light cystoscopy when used for transurethral resection.

Tumor Recurrence Rate and Survival Outcomes of Uterine Serous Carcinoma after Surgical Treatment

2020 ◽  
Vol 103 (10) ◽  
pp. 1083-1090
Keyword(s):  
Overall Survival ◽  
Surgical Treatment ◽  
Recurrence Rate ◽  
Early Stage ◽  
Disease Recurrence ◽  
Serous Carcinoma ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Uterine Serous Carcinoma

Background: Uterine serous carcinoma is a rare histologic subtype of endometrial cancer. Oncologic outcomes for this disease are sparsely reported, and adjuvant therapy after surgery is considerably heterogeneous. Objective: To determine the 2-year recurrence rate, recurrence-free survival, overall survival, and associated factors among patients with uterine serous carcinoma after surgical treatment at Siriraj Hospital. Materials and Methods: One hundred thirty uterine serous carcinoma patients diagnosed between December 2007 and June 2015 were enrolled. Patients who did not undergo surgery as a primary treatment or not achieve clinically complete response were excluded. Pathological slides were reviewed. Data were retrieved from the medical records including gynecologic data, surgical and pathological results, post-operative treatment, response status, recurrence status, and follow-up data. The recurrence rate at two years was calculated. Recurrence-free survival and overall survival were analyzed, and various characteristics were used to determine associated treatment outcomes. Results: One hundred nine patients were analyzed, 50 in stage I, 15 in stage II, 38 in stage III, and six in stage IV. Median follow-up time was 23 months. At two years, the recurrence rate was 35.8%. Post-operative treatment was performed in 91.7%, and chemotherapy was the most common modality used. Eleven patients (16.9%) in early-stage and twenty-five patients (56.8%) in the advanced stage had disease recurrence. Thirty patients (83.3%) had disease recurrence intra-abdominal or multiple metastases. No patient in stage I that received adjuvant chemotherapy had relapsed disease. Two-year recurrence-free survival and 2-year overall survival were 71.2% and 83.4%, respectively. FIGO staging was the only factor associated with recurrence-free survival. Conclusion: Uterine serous carcinoma represents a rare disease with a high recurrence rate and poor prognosis. FIGO staging is related to recurrence-free survival. Adjuvant chemotherapy showed survival benefits in early-stage uterine serous carcinoma. Keywords: Uterine serous carcinoma, Adjuvant therapy, Recurrence, Survival

Sign in / Sign up

Export Citation Format

Share Document